Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced additional data from the first Phase 3 clinical trial of ITI-007 for the treatment of patients with schizophrenia (ITI-007-301) and the ITI-007 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results